[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003064394A8 - 5-ring heterocycles used as antiviral agents - Google Patents

5-ring heterocycles used as antiviral agents

Info

Publication number
WO2003064394A8
WO2003064394A8 PCT/EP2003/000376 EP0300376W WO03064394A8 WO 2003064394 A8 WO2003064394 A8 WO 2003064394A8 EP 0300376 W EP0300376 W EP 0300376W WO 03064394 A8 WO03064394 A8 WO 03064394A8
Authority
WO
WIPO (PCT)
Prior art keywords
antiviral agents
ring heterocycles
heterocycles used
production
medicines used
Prior art date
Application number
PCT/EP2003/000376
Other languages
German (de)
French (fr)
Other versions
WO2003064394A1 (en
Inventor
Tobias Wunberg
Ulrich Betz
Gerald Kleymann
Susanne Nikolic
Juergen Reefschlaeger
Rudolf Schohe-Loop
Holger Zimmermann
Franz Zumpe
Wolfgang Bender
Kerstin Henninger
Guy Hewlett
Axel Jensen
Joerg Keldenich
Original Assignee
Bayer Ag
Tobias Wunberg
Ulrich Betz
Gerald Kleymann
Susanne Nikolic
Juergen Reefschlaeger
Rudolf Schohe-Loop
Holger Zimmermann
Franz Zumpe
Wolfgang Bender
Kerstin Henninger
Guy Hewlett
Axel Jensen
Joerg Keldenich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Tobias Wunberg, Ulrich Betz, Gerald Kleymann, Susanne Nikolic, Juergen Reefschlaeger, Rudolf Schohe-Loop, Holger Zimmermann, Franz Zumpe, Wolfgang Bender, Kerstin Henninger, Guy Hewlett, Axel Jensen, Joerg Keldenich filed Critical Bayer Ag
Priority to EP03734671A priority Critical patent/EP1472229A1/en
Priority to AU2003239243A priority patent/AU2003239243A1/en
Priority to JP2003564017A priority patent/JP2005521669A/en
Priority to CA002474456A priority patent/CA2474456A1/en
Publication of WO2003064394A1 publication Critical patent/WO2003064394A1/en
Publication of WO2003064394A8 publication Critical patent/WO2003064394A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to 5-ring heterocycles, methods for the production thereof, and the use thereof for the production of medicines used for treating or preventing diseases, particularly medicines used as antiviral agents, particularly against cytomegaloviruses.
PCT/EP2003/000376 2002-01-28 2003-01-16 5-ring heterocycles used as antiviral agents WO2003064394A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03734671A EP1472229A1 (en) 2002-01-28 2003-01-16 5-ring heterocycles used as antiviral agents
AU2003239243A AU2003239243A1 (en) 2002-01-28 2003-01-16 5-ring heterocycles used as antiviral agents
JP2003564017A JP2005521669A (en) 2002-01-28 2003-01-16 5-membered heterocycles for use as antiviral agents
CA002474456A CA2474456A1 (en) 2002-01-28 2003-01-16 5-ring heterocycles used as antiviral agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10203086.3 2002-01-28
DE10203086A DE10203086A1 (en) 2002-01-28 2002-01-28 5-ring heterocycles

Publications (2)

Publication Number Publication Date
WO2003064394A1 WO2003064394A1 (en) 2003-08-07
WO2003064394A8 true WO2003064394A8 (en) 2003-12-24

Family

ID=7713161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/000376 WO2003064394A1 (en) 2002-01-28 2003-01-16 5-ring heterocycles used as antiviral agents

Country Status (6)

Country Link
EP (1) EP1472229A1 (en)
JP (1) JP2005521669A (en)
AU (1) AU2003239243A1 (en)
CA (1) CA2474456A1 (en)
DE (1) DE10203086A1 (en)
WO (1) WO2003064394A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90691C2 (en) * 2004-09-29 2010-05-25 Баер Шеринг Фарма Акциенгезельшафт Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
US9840471B2 (en) 2013-02-19 2017-12-12 Senomyx, Inc. Compounds useful as modulators of TRPM8

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES482789A0 (en) * 1978-08-25 1980-12-01 Thomae Gmbh Dr K PROCEDURE FOR THE PREPARATION OF NEW BENZHIMIDAZOLES REPLACED IN POSITION 5 OR 6 WITH A PYRIDAZINONE RING
US6197975B1 (en) * 1995-12-14 2001-03-06 Merck & Co. , Inc. Antagonists of gonadotropin releasing hormone
AU762077B2 (en) * 1997-12-22 2003-06-19 Bayer Healthcare Llc Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas

Also Published As

Publication number Publication date
JP2005521669A (en) 2005-07-21
DE10203086A1 (en) 2003-07-31
AU2003239243A1 (en) 2003-09-02
WO2003064394A1 (en) 2003-08-07
EP1472229A1 (en) 2004-11-03
CA2474456A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
NL300933I2 (en) Letermovir
WO2005063734A3 (en) Substituted thiophenes
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
WO2003080582A3 (en) Fredericamycin derivatives
WO2004006858A3 (en) Compounds, compositions, and methods employing same
MXPA03010134A (en) Substituted cyclohexane-1,4-diamine derivatives.
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
NO20035025L (en) Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity.
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2004071382A3 (en) Substituted heterocycles
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
HK1093729A1 (en) Substituted quinolones
WO2006089664A3 (en) Heterocyclylamide-substituted imidazoles
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO2003033557A3 (en) Copolymers containing fluorine, method for the production and use thereof
NO20033318D0 (en) 2H-1-benzopyran derivatives, process of manufacture, and pharmaceutical compositions thereof
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
MXPA03008186A (en) Anti-thrombotic carboxylic acid amides, the production thereof and use of the same as medicaments.
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
MXPA04004090A (en) Substituted 1h-quinolin-2-one compounds.
WO2005047278A3 (en) Substituted dihydroquinazolines ii
WO2003024996A3 (en) Antibacterial macrocycles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 32/2003 ADD "DECLARATION UNDER RULE 4.17: - AS TO APPLICANT?S ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT (RULE 4.17(II))."

WWE Wipo information: entry into national phase

Ref document number: 2003734671

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2474456

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003564017

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003734671

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642